All News
EULAR 2025 – Day 3 Report
Highlights from today included presentations on imaging in vasculitis, a debate on whether to treat high risk pre-clinical RA, and EULAR Recommendations on a) Treatment of interstitial lung disease (ILD); b) Physical Activity in people with arthritis; and c) EULAR disease activity score for antiphospholipid syndrome and d) the management of SLE nephritis. Below are a few others that caught my eye today.
Read Article
#EULAR2025 Abstr#LB0003 Post-hoc analyses of Phase 3 RCT: Nerandomilast (with or without Nintadenib combo) in sub-group patients with autoimmune #ILD reported similar lung efficacy and safety over PBO, in line with overall trial population. Diarrhoea was common AE @RheumNow https://t.co/fxRdflCi9W
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In RCT of RA pts in remission/low disease activity, spacing ozoralizumab (next gen TNFi) or reducing MTX led to more flares vs continued tx; but most pts in remission at baseline maintained LDAS.
Remission matters for subsequent Tx reduction.
@RheumNow #EULAR2025 #LB0006
Mrinalini Dey DrMiniDey ( View Tweet)
#EULAR2025 Abstr#LB0004 Phase 2 RCT of first-in-class, Enpatoran, TLR7/8-i in active #SLE despite SOC (Cohort B) reported nominal improvement in BICLA but no dose-dependent response. Greater effects seen on active CLE, high IFN-GS or high dose GC. No major safety signal @RheumNow https://t.co/aX4ier0rAy
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
Enpatoran (TLR7/8 inhibitor) in SLE & CLE
- helps skin, others?
- suppresses interferon
lowest dose was highest response though (upsetting primary endpoint)
Promising, watch for the ph3
No photos allowed, but official slides:
https://t.co/1yX6XrYvKH
#EULAR2025 LB0004 @RheumNow
David Liew drdavidliew ( View Tweet)
APEX study Ph3 RCT Guselkumab
In BioNaive active PsA w/ erosions>=2
wk 24
ACR20 GUS Q4W 67% Q8W 68% vs PBO 47%
Less Rx progression in both Q4W & Q8W vs. PBO
#EULAR2025 @RheumNow LB0010 https://t.co/OVDWWECtOZ
Aurelie Najm AurelieRheumo ( View Tweet)
#EULAR2025 Abstr#LB0005 Phase IIb RCT in moderate #Sjogren reported significant reduction in ESSDAI at WK24 from BL in HCQ-Leflunomide vs PBO. CRESS & STAR improved. No significant difference in UWS, Schirmer, & ESSPRI. Future work: cohort of high symptom burden @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
🦵🏻SAP-001, a novel uricosuric targeting a non-URAT1 renal transporter, lowered sUA <6 mg/dL in up to 79% of patients with refractory #gout on b/g xanthine oxidase inhibitor. >50% on 60 mg/day reached sUA <3 mg/dL.
💊Potential new oral ULT option.
@RheumNow #EULAR2025 #LB0008 https://t.co/dfY1V5sHSh
Mrinalini Dey DrMiniDey ( View Tweet)
EULAR PtC for definition of #TR Trt Refractory) #Psoriatic_Arthritis
#D2M
1️⃣ Failure >= 2 b/tsDMARDs
2️⃣ Problematic
3️⃣ Evidence of persistent dis
+
4️⃣ Exclude drivers like comorbidities & psychosocial factors
🔺️Exclude failure due to Side Effets/CI
#EULAR2025
@RheumNow https://t.co/ULD2Xe6p6A
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#GameChanger
Subset analysis of #CTD Pts with
Progressive pulmonary fibrosis
#PPF
Ok background #nintedanib 1/3
❎lung IS
2 doses #PDE4Bi #nerandomilast vs #PBO
each dose ⬇️worsening #FVC vs PBO
⬇️lung events - hospital
⬇️death
GI A/E
#EULAR2025 Latebreakers I @RheumNow https://t.co/PWKEnpyyMN
Links:
Janet Pope Janetbirdope ( View Tweet)
#EULAR2025 Abstr#POS0301 Real World Multicentre study in Italy reported higher proportion of CRR at 6-mth & Lower GC in people with #lupus nephritis (~96% Class III, IV or Mixed with V) treated with Belimumab+SOC vs matched cohort on SOC. Predicted by early BEL use @RheumNow https://t.co/D6e2qo9NRL
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
✅Exciting results from POETYK PsA-1: -Deucravacitinib (TYK2i) in PsA
-ACR 20 was achieved in significantly more patients treated with deucravacitinib vs placebo at W16 (54.2% vs 34.1%; P < 0.0001), with similar results for ACR 50 and ACR 70
-Also met 2dary endpoints.
-Post hoc https://t.co/S4DhovMCma
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Targets for OA pain pharmacotherapies
some by the wayside:
- NGF
- TrkA
but some very much in play and exciting:
- neurotrophin-3
- TRPV1
- Nav1.7, 1.8
Fiona Watt #EULAR2025 @RheumNow https://t.co/DXDKNnVRRo
David Liew drdavidliew ( View Tweet)
#TDM for #HCQ warns of #toxic #levels in #CRF
v low GFR <30, <60, <90, >90
400mg/d all in low GFR toxic
200mg/d 25% in low GFR toxic
6mg/kg/d – low GFR is too ⬆️
adjust HCQ dose for pts with CRF
POS0987 #EULAR2025 @RheumNow @eular_org https://t.co/vg2b87LuiE
Links:
Janet Pope Janetbirdope ( View Tweet)
#EULAR2025 Take Home message from Updated EULAR Recommendations @eular_org for #Lupus Nephritis:
-Kidney Biopsy vital
-Early use of Combination Therapies (HCQ + GC + Immunosuppressant + CNI/Belimumab/Obinutuzumab)
-Severe: High dose Cyclo + GC
@RheumNow https://t.co/jHFqdT1TLf
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
E3N cohort 78000+ women >30yrs follow up
698 incident RA cases)
In non smokers, RA asso w/
-tall at birth HR=1.55
In smokers, RA risk associated w/
-prematurity HR=1.63
-in utero exposure to tobacco HR=1.83 (ns)
#EULAR2025 @RheumNow POS0226 https://t.co/xC3k3kiKsZ
Aurelie Najm AurelieRheumo ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
What happens to the prevalence of D2T PsA if we use different parameters in its definition?
Data from 5 Nordic registries including 13,872 patients showed a variation from 37% (less stringent) to 0.6% (more stringent)!
OP0177
#EULAR2025
@rheumnow https://t.co/QbF15t3Zrz
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Maybe the pathogenesis gives us a clue on how to target things?
Possibly the treatments which take down synovitis might not always help with nodules
Christopher Edwards #EULAR2025 @RheumNow https://t.co/T6QHCS8709
Links:
David Liew drdavidliew ( View Tweet)
